Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia
Open Access
- 27 January 2024
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 45, 113-116
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsClinical Cancer Research, 2023
- Amivantamab (JNJ-61186372)-induced adverse cutaneous reactionIndian Journal of Dermatology, Venereology and Leprology, 2023
- Histological Features Associated With Human Mpox Virus Infection in 2022 Outbreak in a Nonendemic CountryClinical Infectious Diseases, 2022
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyJournal of Clinical Oncology, 2021
- Gefitinib-induced skin ulceration in metastatic adenocarcinoma lungIndian Journal of Medical and Paediatric Oncology, 2014
- Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complexIndian Journal of Dermatology, 2014
- Cutaneous side-effects of EGFR inhibitors and their management.2011
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal DifferentiationJournal of Investigative Dermatology, 1997
- Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal AppendagesJournal of Investigative Dermatology, 1984